UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November~~March 820, ~~2024~~2025

ANIXA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-37492		11-2622630
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3150 Almaden Expressway, Suite 250 San Jose, CA		95118
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (408) 708-9808

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		ANIX		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7 5.~~01.~~07 ~~Regulation~~Submission FDof ~~Disclosure~~Matters to a Vote of Security Holders.

On ~~November~~March 820, ~~2024~~2025, Anixa Biosciences, Inc. (~~“we,”~~the “~~us,~~Company”) ~~“our,”~~completed orits 2025 annual meeting of stockholders (the “~~Company~~Annual Meeting”). ~~issued a~~The ~~press~~number ~~release~~of ~~announcing~~shares ~~that~~of stock entitled to vote at the ~~Company~~Annual ~~and~~Meeting ~~The~~was ~~Cleveland~~32,196,862 ~~Clinic~~shares ~~Foundation~~of common stock (~~“Cleveland~~the ~~Clinic~~“Voting Stock”). ~~presented~~The ~~new~~number of shares of Voting Stock present or represented by valid proxy at the Annual Meeting was 20,691,253 ~~updated~~shares. ~~positive~~At ~~data~~the ~~for~~Annual Meeting, the ~~Phase~~Company’s 1stockholders ~~study~~(i) ofre-elected ~~its~~Dr. ~~breast~~Amit ~~cancer~~Kumar, ~~vaccine~~Dr. ~~The~~Arnold ~~press~~Baskies, ~~release~~Emily Gottschalk, ~~which~~and isLewis H. ~~furnished~~Titterton, Jr. as ~~Exhibit~~directors, ~~99.1~~(ii) ~~hereto~~approved, ~~was~~on ~~issued~~a non-binding, advisory basis, the Company’s executive compensation, (iii) ratified ~~following~~the aappointment ~~presentation~~of ~~made~~Haskell by& ~~Dr.~~White ~~Emily~~LLP ~~Rhoades~~as the Company’s independent registered public accounting firm for the fiscal year ending October 31, ~~FDA/IND~~2025 ~~Trial~~and ~~Program~~(iv) ~~Manager~~selected, aton ~~Cleveland~~a ~~Clinic.~~non-binding, ~~Furnished~~advisory ~~hereto~~basis, one year as ~~Exhibit~~the ~~99.2~~frequency of conducting future stockholder advisory votes on named executive officer compensation. The following is a tabulation of the ~~poster~~voting ~~utilized~~on bythe ~~Dr.~~proposals ~~Rhoades~~presented ~~for~~at the ~~presentation.~~Annual Meeting:

~~Statements~~Proposal ~~that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995~~No. ~~Forward-looking~~1 statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-~~looking~~ ~~statements.~~Election ~~Such forward-looking statements, including those concerning our clinical trials, involve risks, uncertainties and other factors, some~~ of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in “Item 1A - Risk Factors” and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this Current Report.directors

Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. were each re-elected to serve until the 2026 annual meeting of stockholders or until their successors are elected and qualified or until their earlier resignation or removal. The voting results were as follows:

Nominee	Shares Voted For		Shares Withheld		Broker Non-Vote
Dr. Amit Kumar		10,047,287		102,451		10,541,515
Dr. Arnold Baskies		9,958,291		191,447		10,541,515
Emily Gottschalk		9,933,900		215,838		10,541,515
Lewis H. Titterton, Jr.		9,782,175		367,563		10,541,515

Proposal No. 2 - Approval, by non-binding advisory vote, of the Company’s executive compensation

The Company’s executive compensation, by non-binding advisory vote, was approved. The voting results were as follows:

Votes For				Votes Against				Abstentions				Broker Non-Votes
	6,614,575				3,364,480				170,683				10,541,515

Proposal No. 3 - Ratification of the appointment of independent registered public accounting firm

The appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending October 31, 2025 was ratified. The voting results were as follows:

Shares Voted For				Shares Voted Against				Shares Abstaining				Broker Non-Vote
	19,941,654				186,531				563,068				-

Proposal No. 4 - Approval, by non-binding advisory vote, on the frequency of advisory votes on the Company’s executive compensation

The frequency of one year for future advisory votes on the Company’s executive compensation was approved by non-binding advisory vote. The voting results were as follows:

3 Years				2 Years				1 Year				Abstentions				Broker Non-Vote
	1,058,421				168,766				8,735,450				187,101				10,541,515

Item 7.01 Regulation FD Disclosure.

Attached as Exhibit 99.1 to this Current Report is the form of presentation of the Company which was used by management at its Annual Meeting. This presentation may be used by the Company in the future at meetings with investors, analysts or others, in whole or in part and possibly with modifications from time to time.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit No.		Description
99.1		~~Press Release~~Presentation
99.2		Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: ~~November~~March 821, ~~2024~~2025

	ANIXA BIOSCIENCES, INC.

	By:	/s/ Michael J. Catelani
	Name:	Michael J. Catelani
	Title:	President, Chief Operating Officer and Chief Financial Officer

Filing Compare · Anixa Biosciences Inc